EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: BAN2401 2.5 mg/kgDrug: BAN2401 5 mg/kgDrug: BAN2401 10 mg/kgDrug: Placebo
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT02094729
A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.
Phase 2
Completed
- Conditions
- Down Syndrome
- Interventions
- Drug: E2020-Donepezil hydrochlorideDrug: Placebo
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02094053
A Phase 1 Comparative Study of E2022 Current and New Patch Formulations
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: E2022- Current Formula TapeDrug: E2022 Matching Placebo- Current Formula TapeDrug: E2022- New Formula TapeDrug: E2022 Matching Placebo- New Formula Tape
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT02042729
A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects
- First Posted Date
- 2013-12-25
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02020486
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2747
- Registration Number
- NCT01850966
A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males
Phase 1
Completed
- Conditions
- Healthy Elderly Male
- Interventions
- Drug: E2022 Tape Formulation
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT01843556
A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01774773
A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT01773434
A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)
Phase 1
Completed
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: E6011 Matching Placebo
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT01731275
A Study of E7080 in Subjects With Advanced Thyroid Cancer
Phase 2
Completed
- Conditions
- Thyroid Cancer
- Interventions
- Drug: E7080 capsule
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT01728623